The need for phosphoproteomic approaches in psychiatric research

Journal of Psychiatric Research

Volumn 45, Issue 10, 2011, Pages 1404-1406

  Martins de Souza, Daniel ^a   Guest, Paul C ^b   Vanattou Saifoudine, Natacha ^b   Wesseling, Hendrik ^b   Rahmoune, Hassan ^b   Bahn, Sabine ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYNAMIN I; GLYCOGEN SYNTHASE KINASE; TAU PROTEIN;

BINDING SITE; FRAGMENTATION REACTION; HUMAN; LETTER; MEDICAL RESEARCH; MENTAL DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEOMICS; PSYCHIATRY; REGULATORY MECHANISM; TRANSCRIPTOMICS;

EID: 80053114334     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2011.04.007     Document Type: Letter

References (30)

1. Ahn N.G., Resing K.A. Toward the phosphoproteome. Nature Biotechnology 2001, 19:317-318.
2. Ashman K., Villar E.L. Phosphoproteomics and cancer research. Clinical and Translational Oncology 2009, 11:356-362.
3. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 2006, 6:3414-3425.
4. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. Journal of Neuroscience 2007, 27:881-885.
5. Chong P.K., Lee H., Kong J.W., Loh M.C., Wong C.H., Lim Y.P. Phosphoproteomics, oncogenic signaling and cancer research. Proteomics 2008, 8:4370-4382.
6. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Current Topics in Medicinal Chemistry 2006, 6:579-595.
7. Crozatier C., Farley S., Mansuy I.M., Dumas S., Giros B., Tzavara E.T. Calcineurin (protein phosphatase 2B) is involved in the mechanisms of action of antidepressants. Neuroscience 2007, 144:1470-1476.
8. Filiou M.D., Bisle B., Reckow S., Teplytska L., Maccarrone G., Turck C.W. Profiling of mouse synaptosome proteome and phosphoproteome by IEF. Electrophoresis 2010, 31:1294-1301.
9. Gerber D.J., Hall D., Miyakawa T., Demars S., Gogos J.A., Karayiorgou M., et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8993-8998.
10. Groth R.D., Dunbar R.L., Mermelstein P.G. Calcineurin regulation of neuronal plasticity. Biochemical and Biophysical Research 2003, 311:1159-1171.
11. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. The Journal of Biological Chemistry 2007, 282:23645-23654.
12. Hanger D.P., Seereeram A., Noble W. Mediators of tau phosphorylation in the pathogenesis of Alzheimer's disease. Expert Review of Neurotherapeutics 2009, 9:1647-1666.
13. Hernandez F., Avila J. Tauopathies. Cellular and Molecular Life Science 2007, 64:2219-2233.
14. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Current Drug Targets 2006, 7:1421-1434.
15. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Letters 2004, 560:115-119.
16. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F.M., Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Molecular Psychiatry 2010, 15:1088-1100.
17. Levin Y., Jaros J.A., Schwarz E., Bahn S. Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis. Journal of Proteomics 2010, 73:689-695.
18. Macek B., Mann M., Olsen J.V. Global and site-specific quantitative phosphoproteomics: principles and applications. Annual Review of Pharmacology and Toxicology 2009, 49:199-221.
19. Martins-de-Souza D., Dias-Neto E., Schmitt A., Falkai P., Gormanns P., Maccarrone G., et al. Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry 2010, 11:110-120.
20. Martins-de-Souza D., Wobrock T., Zerr I., Schmitt A., Gawinecka J., Schneider-Axmann T., et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World Journal of Biological Psychiatry 2010, 11:719-728.
21. Martins-de-Souza D., Harris L.W., Guest P.C., Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxidants & Redox Signal 2011.
22. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
23. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., et al. Proline-directed and non-proline-directed phosphorylation of PHF-tau. The Journal of Biological Chemistry 1995, 270:823-829.
24. Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Kéri G., et al. Large-scale proteomics analysis of the human kinome. Molecular and Cellular Proteomics 2009, 8:1751-1764.
25. Semenov A., Goldsteins G., Castren E. Phosphoproteomic analysis of neurotrophin receptor TrkB signaling pathways in mouse brain. Cellular and Molecular Neurobiology 2006, 26:163-175.
26. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
27. Walaas S.I., Greengard P. Protein phosphorylation and neuronal function. Pharmacological Reviews 1991, 43:299-349.
28. Wiśniewski J.R., Nagaraj N., Zougman A., Gnad F., Mann M. Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. Journal of Proteome Research 2010, 9:3280-3289.
29. Yamada K., Gerber D.J., Iwayama Y., Ohnishi T., Ohba H., Toyota T., et al. Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:2815-2820.
30. Zhang G., Fang B., Liu R.Z., Lin H., Kinose F., Bai Y., et al. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. Journal of Proteome Research 2010, 10:305-319.